GREENBRAE, CA, MEDFORD, MA / ACCESSWIRE / September 25, 2017 / Dr. Peter Uzelac, a Reproductive Endocrinologist with the Marin Fertility Center in Greenbrae, CA, and INVO Bioscience, Inc. (OTC: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell™, announced today that the first babies to be successfully conceived in California using the INVOcell technology were born in August in San Francisco.
Marin Fertility Center has been offering the INVOcell and INVO procedure since late 2016, when the twins were conceived. Dr. Uzelac said, "This technology simplifies the IVF process, driving down the cost to make it more accessible to patients that would not otherwise be able to afford care."
The mother of the twins, a 30-year-old woman, had tubal factor infertility and had been trying for two years to conceive. Dr. Jennifer Agard, a reproductive endocrinologist with Marin Fertility Center since 2015, was the lead doctor treating the patient looking for a more cost-effective alternative to traditional IVF.
"INVO Bioscience is delighted to have Marin Fertility Center furthering our mission in California to provide affordable, safe and effective treatment for infertility," said Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience. "Drs. Uzelac and Agard, along with the team at Marin Fertility Center, were early adopters of the INVOcell Intravaginal Culture System, and we share in the joy of family building for these deserving patients."
Dr. Uzelac continued, "We are thrilled to be part of this family's story and excited that we can offer our patients a more cost-efficient solution to infertility treatment. INVOcell is an excellent choice for those patients who desire a less invasive experience during their fertility treatment."
The INVOcell is a small capsule that is used in infertility treatment for the incubation of eggs, sperm and embryo development. Unlike conventional infertility treatments such as in vitro fertilization (IVF), where the eggs and sperm develop into embryos in a laboratory, the INVOcell utilizes the woman's vagina as a natural incubator to support embryo development. INVOcell technology offers patients a more personal approach to achieving pregnancy, decreasing the risk of multiple births and reduces the chance for creating unused embryos.
About Marin Fertility Center:
Marin Fertility Center is Northern California's premiere fertility program, offering personalized care using a number of novel treatment approaches, including INVOcell, IVM and Moderate IVF. Marin Fertility Center uses new technology to reimagine the patient experience, reducing the amount of medication and the number of office visits required, resulting in less prohibitive costs. The clinic is led by Dr. Peter Uzelac, a Board-Certified expert in Reproductive Endocrinology and Infertility.
For more information about INVOcell treatment at Marin Fertility Center visit: www.marinfertility.com or contact Jamie Vigil, 415-925-9409, [email protected].
About INVO Bioscience:
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com/.
Safe Harbor Statement:
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Kathleen Karloff, CEO
INVO Bioscience, Inc.
978-878-9505 ext. 504
[email protected]
SOURCE: INVO Bioscience, Inc.